KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC Kiniksa Pharmaceuticals International, plc Share Price
Equities
KNSA
GB00BRXB0C07
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.45 USD | +2.50% |
|
-2.74% | +5.19% |
| 07-01 | Kiniksa Pharmaceuticals Files $400 Million Mixed Shelf | MT |
| 06-26 | Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday | MT |
| Sales 2024 * | 389M 30.68B | Sales 2025 * | 536M 42.28B | Capitalization | 1.31B 103B |
|---|---|---|---|---|---|
| Net income 2024 * | -7M -552M | Net income 2025 * | 42M 3.31B | EV / Sales 2024 * | 2.75 x |
| Net cash position 2024 * | 242M 19.09B | Net cash position 2025 * | 386M 30.43B | EV / Sales 2025 * | 1.73 x |
| P/E ratio 2024 * |
-173
x | P/E ratio 2025 * |
31.6
x | Employees | 297 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kiniksa Pharmaceuticals International, plc
More recommendations
More press releases
| 1 day | +2.50% | ||
| 1 week | -2.23% | ||
| Current month | -1.18% | ||
| 1 month | -2.95% | ||
| 3 months | -6.35% | ||
| 6 months | +5.19% | ||
| Current year | +5.19% |
1 week
17.38
19.00
1 month
17.3819.84
Current year
16.5622.09
1 year
13.5622.09
3 years
7.3622.09
5 years
5.0128.67
10 years
5.0132.88
| Managers | Title | Age | Since |
|---|---|---|---|
Eben Tessari
FOU | Founder | 42 | 30/06/15 |
Sanj Patel
CEO | Chief Executive Officer | 54 | 30/06/15 |
Mark Ragosa
DFI | Director of Finance/CFO | 50 | 30/04/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 30/09/15 |
Barry Quart
BRD | Director/Board Member | 67 | 30/09/15 |
Thomas Malley
BRD | Director/Board Member | 55 | 30/11/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% | ||
| 0.05% | 0 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/07/24 | 18.45 | +2.50% | 413,389 |
| 01/07/24 | 18 | -3.59% | 530,300 |
| 28/06/24 | 18.67 | +0.43% | 1,825,928 |
| 27/06/24 | 18.59 | +0.32% | 409,484 |
| 26/06/24 | 18.53 | -2.32% | 332,693 |
Delayed Quote Nasdaq, July 02, 2024 at 09:00 pm
More quotes
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Calendar
30/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
18
USD
Average target price
30.67
USD
Spread / Average Target
+70.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.19% | 1.28B | |
| +16.44% | 122B | |
| +18.94% | 114B | |
| +19.62% | 25.71B | |
| -25.37% | 19.02B | |
| -20.21% | 15.83B | |
| -20.20% | 15.32B | |
| -47.37% | 14.88B | |
| +59.91% | 14.82B | |
| +4.35% | 14.1B |
- Stock Market
- Equities
- KNSA Stock
